StockNews.com assumed coverage on shares of MEI Pharma (NASDAQ:MEIP – Free Report) in a report published on Thursday morning. The firm issued a buy rating on the stock.
A number of other equities research analysts also recently weighed in on MEIP. Laidlaw downgraded MEI Pharma from a buy rating to a hold rating in a research report on Tuesday, July 23rd. Brookline Capital Management lowered MEI Pharma from a strong-buy rating to a hold rating in a research note on Monday, July 22nd. Three equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. According to MarketBeat.com, the company has an average rating of Hold and an average price target of $7.00.
Get Our Latest Analysis on MEIP
MEI Pharma Trading Down 1.0 %
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in MEI Pharma stock. National Bank of Canada FI acquired a new position in shares of MEI Pharma, Inc. (NASDAQ:MEIP – Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 6,000 shares of the company’s stock, valued at approximately $36,000. National Bank of Canada FI owned approximately 0.09% of MEI Pharma as of its most recent SEC filing. Institutional investors own 52.38% of the company’s stock.
About MEI Pharma
MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
Featured Stories
- Five stocks we like better than MEI Pharma
- Top Biotech Stocks: Exploring Innovation Opportunities
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- 3 Grocery Stocks That Are Proving They Are Still Essential
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- What is a Low P/E Ratio and What Does it Tell Investors?
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.